SR133 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
SR133 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed SR133 in detail.
, Flavonoid compound of red fruit papua and its derivatives against sars-cov-2 mpro: An in silico approach, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2024.177392
In the past years, the world has experienced a profound impact due to the abrupt appearance of a new virus (COVID-19), presenting a significant threat to human health. Currently, there exists no widely established treatment for COVID-19 that proves consistently effective, but many studies have implemented drug repurposing and the use of herbal medicines. The potential of antiviral compounds from natural products can be predicted through an in silico approach. This study aimed to determine and design flavonoid compounds from red fruits and their derivatives that have the potential to suppress the SARS-CoV-2 Mpro, ensuring a stable molecular framework and adhering to a standard pharmacokinetic profile. The study started with molecular docking using a lead compound followed by Molecular dynamics (MD) simulation up to 100 ns and pharmacokinetic prediction. The analysis of docking outcomes reveals that among flavonoid compounds, quercetin 3’-glucoside exhibits the most favourable binding energy value. Furthermore, the identification of hydrogen bonds with amino acid residues Asn142 and Cys145 provides additional rationale for selecting this compound as a pivotal candidate in the design of novel derivatives. The molecular docking procedure and subsequent MD simulations were conducted utilizing the Yasara-structure software. Furthermore, the evaluation of the pharmacokinetic profile was performed utilizing pkCSM ADMET to gain insights into the compound’s absorption, distribution, metabolism, excretion, and toxicity characteristics. According to the docking outcomes, among the 225 newly designed compounds, the ligand with code SR133 demonstrated the most favourable binding energy of −8.0950 Kcal/mol, surpassing the reference compound. Subsequent MD simulation analysis indicates that this ligand demonstrates good stability. The presence of hydrogen bonds in the active site of SARS-CoV-2Mpro involving the main amino acid residues Asn142 and Cys145 further clarifies that this new compound has excellent inhibitory potential. The pharmacokinetic prediction of SR133 shows that this compound has a good pharmacokinetic profile and is worth proposing as a new drug candidate.